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a b s t r a c t
The Pregnane X Receptor (PXR) is a key regulator of enzymes, for example the cytochrome P450 isoform
3A4 (CYP3A4), and transporters involved in the metabolism and excretion of xenobiotics and endogenous
compounds. Activation of PXR by xenobiotics causes altered protein expression leading to enhanced or
decreased turnover of both xenobiotics and endogenous compounds. This can potentially result in pertur-
bations of normal physiology and adverse effects. Identification of PXR activating and CYP3A4 inducing
compounds is included in drug-discovery programs but we still need similar information for the remain-
ing tens-of-thousands of man-made compounds to which humans are potentially exposed. In the present
study, we used high-throughput in vitro assay results for 2816 drugs to develop four quantitative
structure-activity relationship (QSAR) models with binary outputs for binding to the human PXR ligand
binding domain, full-length human and rat PXR activation and human CYP3A4 induction, respectively.
Rigorous cross- and blinded external validations demonstrated four robust and highly predictive models
with balanced accuracies ranging from 75.4% to 92.7%. The models were applied to screen 72,524 sub-
stances pre-registered under the EU chemicals regulation, REACH, and the models could predict 52.5%
to 71.9% of the substances within their respective applicability domains. These predictions can, for exam-
ple, be used for priority setting and in weight-of-evidence assessments of chemicals. Statistical analyses
of the experimental drug dataset and the QSAR-predicted set of REACH substances were performed to
identify similarities and differences in frequencies of overlapping positive results for PXR binding, PXR
activation and CYP3A4 induction between the two datasets.
 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The nuclear receptor (NR) superfamily is a large group of tran-
scription factors that control expression of multiple genes involved
in a broad range of biological processes, such as development,
homeostasis and metabolism. The transcriptional activity of NRs
is primarily regulated through ligand binding [1]. The Pregnane X
Receptor (PXR), first described by Kliewer and colleagues in
1998, is a member of the NR superfamily [2,3]. PXR is mainly
expressed in the liver, intestine and kidneys, and plays a key role
in the regulation of genes involved in the metabolism and efflux
of endogenous hormones and xenobiotic molecules [3–5]. The
genes regulated by PXR include genes encoding enzymes, such as
cytochrome P450s (CYPs), glucuronyltransferases and sulfotrans-
ferases, as well as transporters, such as P-glycoprotein and mul-
tidrug resistance proteins [2,3,6–8]. The ligand-binding domain
(LBD) of PXR is large and flexible, and can change its shape to
accommodate structurally diverse molecules including steroids,
bile acids, antibiotics, statins, and pesticides [9,10]. A considerable
amount of inter-species variation has been observed in the PXR
LBD with human, rabbit and rat sharing roughly 75–80% amino
acid identity [11,12]. There are numerous examples of differences
in ligand binding to PXR and resulting downstream transcription
http://dx.doi.org/10.1016/j.comtox.2017.01.001
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of enzymes and transporters between species, which complicates
the extrapolation of results from in vivo animal studies to humans
[11,13–15].
PXR is located in the cytoplasm and translocated to the nucleus
upon ligand binding, and here the PXR-ligand complex
heterodimerizes with the Retinoid X Receptor alpha (RXRa),
another member of the NR superfamily. The PXR-RXRa heterodi-
mer complexes with co-activators, and this multi-protein complex
binds to the Xenobiotic Response Element (XRE) in the promoter
region of target genes and induces their transcription leading to
altered expression of their encoded proteins [2,3,16]. Because
many of the proteins regulated by PXR are not only involved in
the metabolism and transport of xenobiotics, but also of various
endogenous compounds such as steroid and thyroid hormones,
an altered protein expression upon xenobiotic exposure may inter-
fere with the homeostatic balance of such endogenous compounds
[17,18]. This interference can potentially affect normal physiologi-
cal functions [2,19] and may result in adverse health effects. Find-
ings from previous studies indicate that there is an association
between PXR activation by environmental chemicals and adverse
health effects [15,18,20,21]. The importance of PXR activation is
also reflected in a number of suggested adverse outcome pathways
(AOPs) available from the online AOP-Wiki [22], for example an
AOP describing how activation of PXR and other related NRs upreg-
ulate thyroid hormone catabolism resulting in hypothyroidism and
subsequent adverse neurodevelopmental outcomes [23]. The AOPs
are envisioned to promote the industry’s and regulators’ use of
results from alternative methods such as in vitro tests and compu-
tational models in chemical risk assessments to reduce, refine or
replace traditional animal tests [24–26], for example by applying
the AOP in an Integrated Approaches to Testing Assessment (IATA)
context to support regulatory decisions [27].
PXR is also known to be involved in drug-drug interactions in
which an administered drug affects the metabolism and excretion
of a co-administered drug, leading to decreased efficacy or
increased toxicity [2,28,29]. For this reason, attenuation of PXR
activity has become an important focus area in early drug-
discovery programs [30]. Similar to drug-drug interactions, an
altered expression of enzymes and transporters through PXR acti-
vation upon xenobiotic exposure may cause changes in the
response to other xenobiotic compounds.
Among the many PXR target genes is the gene encoding
CYP3A4, an oxidizing enzyme involved in phase I metabolism of
various compounds [4,31]. CYP3A4 is considered the main drug-
metabolizing CYP isoform in the human liver and is involved in
the metabolism of more than 50% of drugs on the market [2,5].
In most cases, CYP3A4 causes chemicals to become less biologically
active and promotes their excretion; but in other cases it has the
opposite effect causing bioactivation by converting them to
metabolites that are more toxic than the parent molecule [32].
Because xenobiotic activation of PXR has the potential to alter
normal physiology and lead to adverse effects, it is of great impor-
tance to identify chemicals that may act through this mechanism.
In a study from 2011, Shukla and colleagues used four high-
throughput in vitro assays to profile more than 2800 clinically-
used and investigational drugs for their ability to bind to the
human PXR-LBD, activate full-length human and rat PXR, and
induce human CYP3A4 [14]. Chemicals in the ToxCast program
[33], which include both drugs and environmental chemicals, have
also been tested for these mechanisms in related assays [34]. How-
ever, we still need similar information for the remaining tens-of-
thousands of xenobiotics to which humans are potentially exposed
[35,36].
In the present study, we used the high-throughput in vitro
data from Shukla et al. [14] to train and validate four Quantitative
Structure-Activity Relationship (QSAR) models for human PXR-
LBD binding, human and rat PXR activation, and human CYP3A4
induction, respectively. QSAR models are computational models
that relate chemical structures to, e.g., a biological activity, and
they can be used to predict the activity of an untested chemical
based on its chemical structure (an introduction to QSAR can
e.g. be found in [37,38]). In general, QSARs are rapid and cost-
effective tools for predicting biological activities of chemical
structures and can be used for virtual screening of single sub-
stances as well as large chemical inventories. The four developed
models were applied to screen a structurally diverse library of
72,524 chemicals from the EU chemicals regulation REACH
(Registration, Evaluation, Authorisation and Restriction of Chemi-
cals) list of Pre-Registered Substances (PRS) [39,40], containing
substances potentially present in our food, the environment and
consumer products. These QSAR predictions can, e.g., be used,
possibly together with other relevant data, 1) to identify and pri-
oritize chemical substances for further testing and 2) in an IATA
context, together with relevant AOP(s), to guide further testing
and regulatory decisions in chemical risk assessments
[25,27,41]. Furthermore, statistical analyses of the experimental
drug dataset and the QSAR-predicted REACH PRS set were per-
formed in order to elucidate similarities and differences in co-
occurrences of overlapping positive results for PXR binding, PXR
activation and CYP3A4 induction between the two chemical
universes.
2. Materials and methods
2.1. Experimental datasets
We used four datasets containing chemical structure informa-
tion and in vitro experimental data for a collection of 2816
clinically-used and investigational drugs to train and validate the
QSAR models. The experimental data of the 2816 compounds
included results from quantitative high-throughput screening
(qHTS) for binding to the LBD of human PXR at the protein level
(hPXR-LBD); activation of full-length human PXR (hPXR) and full-
length rat PXR (rPXR) at the cellular level; and induction of human
CYP3A4 at the cellular level (CYP3A4). All experimental data were
generated by the National Center for Advancing Translational
Sciences (NCATS) at the National Institute of Health (NIH). The
compound collection, qHTS assays, and the classification of the
qHTS results into actives, inconclusives and inactives have been
described previously [14,42,43]. Briefly, actives showed binding
to the hPXR-LBD, activation of hPXR and/or rPXR and/or induced
transcription of CYP3A4 according to the applied assays. Inactives
did not show activity in the given assay, and inconclusives showed
equivocal activity results in the assays. Only the substances in each
dataset classified as either active or inactive were used, i.e. sub-
stances with inconclusive experimental results were excluded.
The experimental results for about one third of the substances in
each of the four main datasets were masked by NIH NCATS and
these compounds were used as external test sets for blinded exter-
nal validations after the model development was finished. The
selection of the test sets was designed and made by NIH NCATS sci-
entists, who clustered all compounds in the dataset on structural
similarity using the Euclidian distance and then, within each struc-
ture cluster and for each of the four endpoints, approximately one-
third actives and one-third inactives were selected randomly. Thus
the training and test sets are structurally comparable and have
similar distributions of actives and inactives. NIH NCATS sent the
training sets containing structure information and experimental
results and the test sets containing only structure information to
the National Food Institute (Food) at the Technical University of
Denmark (DTU), who performed the structure preparations, the
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model development and validations as well as the virtual
screenings.
Furthermore, a dataset containing 4000 additional com-
pounds with experimental data from the qHTS assay for hPXR-
LBD was used for supplementary performance assessment of the
developed hPXR-LBD QSAR model [20,43].
2.2. Structural preparation of the datasets
The commercial QSAR software applied in this study can handle
organic chemical substances with a known and unambiguous 2D
structure. We apply an overall definition of substances acceptable
for QSAR processing in all our in-house QSAR software [44,45], as
substances:
 containing at least two carbon atoms
 containing only H, Li, B, C, N, O, F, Na, Mg, Si, P, S, Cl, K, Ca, Br,
and/or I
 that are not mixtures containing two or more organic
components
Substances that did not fulfil these criteria were removed from
the datasets. Further processing of the structural information
included dissociation simulation and subsequent neutralization
of the structures, i.e. all substances were used in their non-
ionized form. An overview of the number of QSAR-ready sub-
stances in the final training and external test sets after structure
preparation can be found in Table 1. These sets are available upon
request.
2.3. QSAR modeling
We used the commercial software, Leadscope Predictive Data
Miner (LPDM), a component of Leadscope Enterprise Server ver-
sion 3.2.4 [46], to build the four QSAR models. Briefly, LPDM calcu-
lates nine molecular descriptors (AlogP, Hydrogen Bond Acceptors
and Donors, Lipinski Score, Molecular Weight, Parent Atom Num-
ber, Parent Molecular Weight, Polar Surface Area, Rotatable Bonds)
for each chemical structure in the training set and performs a sys-
tematic sub-structural analysis using a template library of more
than 27,000 predefined structural features [47]. The molecular
descriptors and structural features are included in a default initial
descriptor set. In addition, the system can generate and add train-
ing set-dependent structural features (scaffolds) to the descriptor
set as well as remove redundant structural features from the
descriptor set. Once a preliminary descriptor set has been created,
an automatic descriptor selection procedure in LPDM selects the
top 30% descriptors according to Yates X2-test for a binary response
variable. A predictive model for a binary response variable is built
using partial logistic regression (PLR) with further selection of
descriptors in an iterative procedure, and selection of the optimum
PLR factors based on least predictive residual sum of squares.
LPDM has the option of building composite binary models for
training sets with a skewed distribution between the two activity
classes, i.e. actives and inactives. With this option a number of
sub-models are constructed, taking in each sub-model the entire
smaller class, here the actives, and an equally large sample from
the bigger class, here the inactives. The samples from the bigger
class used in each of the sub-models are selected randomly but
in such a way that their intersection is minimal and their union
is the entire bigger class. The positive prediction probability (see
Section 2.4) for a test chemical from a composite model is defined
as the average of the positive prediction probabilities of all sub-
models where the test chemical is in the structural domain [48].
Each sub-model in a composite model has its own unique set of
selected descriptors and number of PLR factors.
We used five different modeling approaches in LPDM to build
five predictive models for each of the four training sets: 1) single,
2) single with scaffolds, 3) single with scaffolds and reduced struc-
tural features, 4) composite, and 5) composite with scaffolds. In 1)
and 4), the descriptors were selected among the default initial
descriptor set, i.e. containing molecular descriptors and selected
predefined structural features, and used to build a single model
and a composite model, respectively. Next, scaffolds were gener-
ated in LPDM from the training set structures and added to the ini-
tial descriptor set, which subsequently was used for descriptor
selection for models 2) and 5). In model 3), the scaffold-enriched
descriptor set was reduced before descriptor selection by removing
most similar structural features using a built-in function in LPDM.
All models underwent a ten times two-fold cross-validation by the
LPDM algorithm, which reuses the selected descriptor set from the
parent model when building the cross-validation models [48]. For
each of the four endpoints, we selected the predictive model with
the highest performance from the LPDM cross-validation for fur-
ther validation and screening studies (Fig. 1). The LPDM cross-
validations were only applied for model selection and not used
for model performance assessments. The four selected models
were ‘closed’ for further development after this selection.
2.4. Applicability domain
Our definition of the applicability domain (AD) consists of two
components: 1) the definition of a structural domain in LPDM,
and 2) an in-house class probability refinement on the output from
LPDM. For a test compound to be within LPDM’s structural domain
it is required that: all molecular descriptors used in the model can
be calculated, it contains at least one structural feature used in the
model, and that it has at least 30% Tanimoto similarity (default cut-
off in the LPDM software) with a training set compound [48]. No
prediction call (active/inactive) is generated by LPDM for a test
compound outside this structural domain. For test compounds
within the LPDM structural domain, a positive prediction probabil-
ity, p, between 0 and 1, is given together with the prediction call;
actives having a pP 0.5 and inactives having a p < 0.5 [48]. To
Table 1
Overview of the sizes of the training sets and the blinded external test sets used to develop and validate the four QSAR models. An extra dataset for hPXR-LBD binding was used
for external validation. Substances with inconclusive experimental results were removed from the datasets.
Datasets Training set External test set
Total Active (%) Inactive (%) Total Active (%) Inactive (%)
hPXR-LBD* 1537 143 (9.3) 1394 (90.7) 651 30 (4.6) 621 (95.4)
hPXR* 1644 207 (12.6) 1437 (87.4) 702 59 (8.4) 643 (91.6)
rPXR* 1671 97 (5.8) 1574 (94.2) 730 24 (3.3) 706 (96.7)
CYP3A4* 1676 179 (10.7) 1497 (89.3) 715 45 (6.3) 670 (93.7)
Extra hPXR-LBD – – – 2434 279 (11.5) 2155 (88.5)
* The experimental results of the test set were masked from the model developers at DTU Food by NIH NCATS until the models were developed and the test set had been
predicted.
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exclude less reliable predictions, i.e. those with a positive predic-
tion probability close to p = 0.5, we required pP 0.7 for active pre-
diction calls and p 6 0.3 for inactive prediction calls. Predictions
within the LPDM structural domain but with an associated positive
prediction probability in the interval 0.3 to 0.7 were defined as out
of AD and excluded from the statistical analyses.
2.5. Cross- and external validation of the models
Each of the four selected predictive models was subsequently
subject to a five times twofold stratified cross-validation procedure
to estimate their robustness and predictive performance (Fig. 1).
The applied procedure did not use the LPDM built-in cross-
validation functionality. Instead, this was done by randomly
removing 50% of the structures from the training set, keeping the
ratio of actives and inactives. Then a cross-validation model was
built from the reduced training set using the same modeling
approach as in the parent model but by performing novel modeling
where no information, such as selected descriptors, was reused
from the parent model. The cross-validation model was applied
to predict the removed 50%. Likewise, a cross-validation model
was made on the removed 50% of the training set, and this model
was used to predict the other 50%. This procedure was repeated
five times resulting in ten cross-validation models. Sensitivity,
specificity and balanced accuracy [49] were calculated for each of
the ten cross-validation models, and from these the mean and
standard deviation (SD) were computed to give an overall statisti-
cal estimate of the predictive performance and robustness of the
full-training set parent model. Sensitivity is the percentage of
experimental actives correctly predicted, specificity is the percent-
age of the experimental inactives correctly predicted, and balanced
accuracy is the average of the sensitivity and specificity [49]. The
coverage, i.e. the mean percentage of how many of the predicted
substances that had predictions within the AD of the ten cross-
validation models, was also calculated.
In addition, all four models underwent a blinded external vali-
dation using the experimentally masked test sets to further evalu-
ate their predictive performance (Fig. 1). The prediction calls
within the AD were compared to the experimental results, which
were made available to DTU Food by NIH NCATS after the model
building step was finalized and the test sets predicted. The hPXR-
LBD model underwent an additional external validation with the
extra test set for hPXR-LBD. This external validation was not
blinded, however, the data set was not applied in any of the model
development or selection steps. Coverage, sensitivity, specificity
and balanced accuracy were calculated for each model.
2.6. Screening of the REACH PRS inventory
The four selected and validated QSAR models were used to pre-
dict the activity of 72,524 substances from the REACH PRS list
(Fig. 1). The REACH PRS chemical structures were extracted from
the online Danish (Q)SAR Database structure set [44,45]. The struc-
tures were originally curated from deliverable 3.4 of the OpenTox
EU project [39] and had been processed through the same struc-
ture preparation steps as described in Section 2.2 to meet the
structural requirements from the QSAR modeling software. The
proportion of the QSAR-predicted REACH PRS within the AD of
each of the four models as well as the activity distributions of
the predictions was calculated.
2.7. Concordance rates between endpoints
To study the co-occurrences in positive results for PXR binding,
PXR activation and CYP3A4 induction, positive concordance rates
both ways between the following endpoints were estimated:
 hPXR-LBD and hPXR,
 hPXR and rPXR, and
 hPXR and CYP3A4.
This was done for the full experimental drug datasets, i.e. the
training and external test set data (excluding the extra hPXR-LBD
test set) combined, as well as for the 60,281 unique structures
out of the 72,524 QSAR-ready REACH PRS (Fig. 1).
For any endpoints, A and B, we used the following definition of
the rate of actives in A also active in B, denoted Concordance rate
(A? B):
Fig. 1. Workflow of the modeling, screening and concordance rate studies.
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Concordance rateðA! BÞ
¼ #active in A AND B
#active in A AND Bþ#active in A AND in active in B
We apply the above definition twice for each pair of endpoints,
A and B, to calculate Concordance rate (A? B) and Concordance rate
(B? A).
For example, to assess the rate of hPXR-LBD ligands that acti-
vate hPXR, the following calculation was made:
Likewise, the concordance rate for hPXR activators that were
also active for binding to hPXR-LBD was calculated as:
Differences and similarities between corresponding
concordance rates in the drug and REACH PRS universes were
identified.
3. Results
3.1 Predictive performance and robustness
For each of the four endpoints the model with the highest per-
formance from the LPDM cross-validation was selected for further
validation and screening studies. The four selected models were all
composite models consisting of seven to ten sub-models. Each of
the four selected models underwent both an in-house rigorous five
times leave-50%-out cross-validation and a DTU Food blinded
external validation to assess their robustness and predictive per-
formance within the defined AD. The validation results are pre-
sented in Table 2 together with information about the number of
sub-models in the selected composite model. Overall, the results
presented in Table 2 show that the rigorous leave-50%-out cross-
validations underestimated the models’ predictive performances
compared to the blinded external validations. The models will be
made available for prediction of user-submitted structures in a
coming free online Danish (Q)SAR Models sister-site to the Danish
(Q)SAR database at the DTU homepage [45].
3.2. Screening of the REACH PRS inventory
A set of 72,524 substances from the REACH PRS list was
screened through the four QSAR models. Of the 72,524 REACH
PRS, 28.6% (20,727) were in the common AD of all four models,
and of these, 1.5% corresponding to 320 substances were predicted
active for all four endpoints and 77.1% corresponding to 15,979
substances were predicted inactive by all four models. The number
of REACH PRS predicted within the defined AD of each model and
the distribution of active and inactive predictions are given in
Table 3.
3.3. Concordance rates between hPXR-LBD binding and Full-Length
hPXR activation
The cell-free hPXR-LBD assay is a LanthaScreen TR-FRET (time
resolved fluorescence resonance energy transfer)-based assay that
identifies binding of a chemical to the LBD of human PXR, whereas
the cell-based hPXR assay identifies compounds that can activate
human full-length PXR either through direct LBD binding or
through other signaling pathways [50,51]. In order to obtain more
information on frequencies of possible mechanisms of PXR activa-
tion for drugs and REACH PRS, we calculated two-way concordance
rates between hPXR-LBD binding and full-length hPXR activation
for the experimental results of the full drug datasets and for the
QSAR predictions of the REACH sets, respectively (Fig. 2a). For the
experimental drug data the rate of hPXR-LBD tested binders result-
ing in hPXR activation was 44.0% (63/(63 + 79)), and the rate of
hPXR activators binding to hPXR-LBD was 37.7% (63/(63 + 104)).
For the predicted REACH substances only compounds in the com-
mon AD of the two models (n = 22,486) were included in the anal-
ysis, and among these 2624 were predicted active by both models
and 16,842 were predicted inactive by both models. Of the remain-
ing 3020 disconcordant predictions, 2408 were predicted active for
hPXR-LBD but inactive for hPXR, while 612 were predicted active
for hPXR but inactive for hPXR-LBD. Based on these predictions,
it was estimated that 52.1% (2624/(2,624 + 2408)) of the predicted
hPXR-LBD actives are also predicted to cause hPXR activation,
whereas 81.1% (2624/(2,624 + 612)) of the predicted hPXR activa-
tors are also predicted to bind to hPXR-LBD.
3.4. Concordance rates between hPXR activation and CYP3A4
induction
Since PXR is known to induce the transcription of CYP3A4
[4,31], we calculated the concordance rates between hPXR activa-
tion and CYP3A4 induction for both the tested drugs and the QSAR-
predicted REACH substances set (Fig. 2b). For the experimental
drug data, the rate of hPXR active drugs that result in CYP3A4
induction was 53.6% (113/(113 + 98)), and the rate of CYP3A4
inducers also activating hPXR was 66.5% (113/(113 + 57)). Of the
24,364 REACH PRS predicted within the common AD of the two
models, 2945 were predicted active by both models, whereas
20,960 were predicted inactive in both models. Among the 459
substances with discrepant predictions, 385 were predicted active
by hPXR only and 74 were predicted active only by the CYP3A4
model. From these numbers it can be estimated that 88.4%
(2945/(2945 + 459)) of the REACH substances predicted to cause
hPXR activation were also predicted to induce CYP3A4, and that
97.5% (2945/(2945 + 74)) of the predicted CYP3A4 inducing REACH
substances were also predicted to activate hPXR.
Concordance rateðhPXR LBD! hPXRÞ
¼ #predicted=tested active in hPXR-LBD AND hPXR
#predicted=tested active in hPXR-LBD AND hPXR þ#predicted=tested active in hPXR  LBD AND in active in hPXR
Concordance rateðhPXR ! hPXR  LBDÞ
¼ #predicted=tested active in hPXR-LBD AND hPXR
#predicted=tested active in hPXR  LBD AND hPXR þ#predicted=tested active in hPXR AND in active in hPXR-LBD
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3.5. Concordance rates between human and rat Full-Length PXR
activation
Species differences in PXR activation by chemicals have previ-
ously been identified [11,14,52] and information on these differ-
ences can be of importance when extrapolating data from rat
in vivo studies to humans, e.g. in chemical risk assessment. In the
experimental drug dataset, the rate of human PXR activating drugs
that also activate the rat PXR was 25.9% (51/(51 + 146)) (Fig. 2c).
Conversely, 56.7% (51/(51 + 39)) of the rat PXR activating drugs
also activated human PXR. To estimate the species differences in
human and rat PXR activation with regard to the QSAR-predicted
REACH substances, we compared REACH PRS QSAR-predictions
from the hPXR and rPXR models. Among the 25,498 REACH PRS
predicted in the common AD, 862 were predicted active in both
models, 2788 were predicted active for hPXR only, and 573 were
predicted active for rPXR only. The remaining 21,275 were pre-
dicted inactive by both models. From this it can be estimated that
23.6% (862/(862 + 2788)) of the QSAR-predicted REACH PRS acti-
vating human PXR were also predicted to activate rat PXR, and
60.1% (862/(862 + 573)) of the predicted rat PXR activators were
also predicted as human PXR activators.
4. Discussion
In the present study, we developed four global binary QSAR
models for human PXR-LBD binding, human and rat full-length
PXR activation, and human CYP3A4 induction, respectively. The
models were used to screen more than 70,000 REACH substances.
To our knowledge this is the first study to profile a large set of
chemical substances potentially used in industrial processes, food
and consumer products, such as cleaning products, paints, clothes,
and furniture, by QSAR with respect to both PXR binding/activation
and CYP3A4 induction.
4.1. Predictive performance and robustness
A number of different modeling approaches in LPDM were used
to build models on the four training sets and the best performing
model for each endpoint was selected for further validation studies
and screening of the REACH PRS inventory. It is known that sensi-
tivity and specificity of binary models can, depending on the
applied modeling algorithm, be affected by the distribution of
actives and inactives in the training set. A training set with a
greater number of inactives will often result in a higher specificity
at the expense of sensitivity and vice versa in the case of overrep-
resentation of actives. This is likely the reason why the single mod-
els built with the full, imbalanced training sets were outperformed
by the composite models: all four selected models were composite
models consisting of seven to ten sub-models with balanced sub-
training sets. The composite model feature in LPDM was imple-
mented to handle imbalanced training sets [48], in this case train-
ing sets with only 5.8% to 12.6% actives.
All four models showed high predictive performances with bal-
anced accuracies in the external validations ranging from 76.1% to
92.7% (Table 2). Both the high quality of the experimental data
originating from robust assays [14,53] as well as the composite
modeling approach in LPDM have undoubtedly contributed to
the high performances of the models. The cross-validation results
were generally pessimistic compared to the external validations
(Table 2), especially with regard to the sensitivity. The fact that
the cross-validation results in this study are pessimistic compared
to the external validations is in accordance with the finding in, e.g.
[54], where this issue was systematically studied. The generally
low standard deviations (SDs) in the cross-validations indicate
robust models, i.e. their performances are not drastically altered
in response to perturbations of the training set composition. Both
the remarkably lower cross-validation sensitivities relative to the
external validation sensitivities and their higher SDs is likely due
to the rigorous cross-validation procedure of removing 50% of
the few actives in the non-congeneric training sets. The effects of
removing 50% is most clearly reflected in the rPXR model (Table 2),
which was also the model with the fewest training set actives, i.e.
97 actives (Table 1). Often k-fold cross-validations of models built
from training sets of similar size as those in this study are
Table 2
Coverage and predictive performance of the four QSAR models. Only predictions inside the defined AD were included in the statistical analyses.
QSAR model Statistical parameter Cross-validation,% (SD,%) External validation,% (actual numbers)
5 times 2-fold* Blinded test sets** Extra hPXR-LBD test set
hPXR-LBD Approach 5) 10 sub-models Coverage 66.0 (3.3) 67.3 (438/651) 60.6 (1475/2434)
Sensitivity 68.7 (7.3) 85.0 (17/20) 71.9 (97/135)
Specificity 84.5 (2.0) 87.8 (367/418) 80.4 (1078/1340)
Balanced accuracy 76.6 (3.2) 86.4 76.1
hPXR Approach 5) 7 sub-models Coverage 60.3 (2.9) 59.1 (415/702) –
Sensitivity 72.5 (6.7) 80.0 (24/30) –
Specificity 80.4 (3.7) 85.2 (328/385) –
Balanced accuracy 76.4 (2.9) 82.6 –
rPXR Approach 4) 10 sub-models Coverage 74.0 (3.0) 80.0 (584/730) –
Sensitivity 58.9 (11.0) 91.3 (21/23) –
Specificity 92.0 (2.4) 94.1 (528/561) –
Balanced accuracy 75.4 (4.7) 92.7 –
CYP3A4 Approach 5) 9 sub-models Coverage 64.7 (3.0) 63.4 (453/715) –
Sensitivity 71.6 (7.6) 76.9 (20/26) –
Specificity 80.7 (2.7) 85.5 (365/427) –
Balanced accuracy 76.1 (3.3) 81.2 –
* A five times twofold cross-validation with same active-inactive ratio as the full training set and without reusing selected descriptors from the parent model. Coverage,
sensitivity and specificity are the mean from the ten cross-validation models with the standard deviation (SD) in parentheses.
** The experimental results of the test set structures were made available to DTU Food by NIH NCATS after they had been predicted in the respective models by DTU Food.
Table 3
Prediction and domain results for the 72,524 REACH PRS.
QSAR model Total
in AD (%)
Predicted Active
in AD (%)
Predicted Inactive
in AD (%)
hPXR-LBD 43,551 (60.1) 11,490 (26.4) 32,061 (73.6)
hPXR 38,114 (52.5) 6167 (16.2) 31,947 (83.8)
rPXR 52,144 (71.9) 3141 (6.0) 49,003 (94.0)
CYP3A4 42,861 (59.1) 5874 (13.7) 36,987 (86.3)
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performed by removing 10% or 20% (i.e., k = 10 or 5) of the training
set, leaving more data to train the cross-validation models [52,54].
The cross-validation results indicate that the leave-50%-out cross-
validation performed in the present study was causing too big per-
turbations. Retrospectively, it seems that a 10 or 20%-leave-out
cross-validation would have been more appropriate in this case.
The hPXR-LBD model in the present study has a lower cross-
validation sensitivity (68.7%) compared to a similar hPXR-LBD
model from Dybdahl and colleagues (82.3%) [14,20,43]. The differ-
ence in sensitivities is likely due to differences in the composition
of the two training sets, with the Dybdahl model having more than
twice as many actives in its training set, i.e. 299 versus 143 actives
in the current model, leaving more actives for the 50% reduced
cross-validation models. Additionally, the Dybdahl model cross-
validation [20] was performed using LPDMs algorithm, which, we
have experienced in some cases, returns overoptimistic statistics
because of its reuse of parent model descriptors in the cross-
validation models.
The size of the DTU Food masked external test sets with predic-
tions inside the respective model’s AD ranged from 415 to 584
structures, with 20–30 structures having active experimental
results (Table 2). In general, external test sets should be sufficiently
large and representative of the model’s AD to ensure that the pre-
dictive performance results are not random. The distributions of
experimentally active and inactive structures in these external test
sets are imbalanced toward more inactives similar to the training
set distributions. Although the masked test sets in total are quite
large for external validation, the few actives make the calculations
of sensitivity less robust. The supplementary external validation of
the hPXR-LBD model included 135 experimentally active sub-
stances out of the total 1475 test set structures predicted inside
the hPXR-LBD model’s AD (Table 2). This larger number of actives
may provide a more accurate estimate of the hPXR-LBD model’s
sensitivity compared to the result from the blinded external valida-
tion with only 20 experimentally active compounds. The extra
external validation of the hPXR-LBD model resulted in overall
lower predictive performance estimates compared to the blinded
external validation (Table 2). This can be due to differences in
the chemical universes of the two test set with the blinded test
set likely representing the training set better due to the
chemical-similarity test set selection procedure described in Sec-
tion 2.1 [55,56]. A previous study have shown that this type of
rational test set selection can give optimistic validation results
[57]. Also, although the hPXR-LBD data in the two datasets were
generated using the same assay protocol in the same laboratory,
minor differences in the data analysis of the extra hPXR-LBD data-
set compared to that of the NIH NCATS hPXR-LBD data could have
negatively affected the validation results to some degree. Available
ToxCast datasets [34] with experimental results for human PXR
binding and activation and CYP3A4 induction were not applied in
the validation study due, in our opinion, to large dissimilarities
in the assay protocols and data analysis with the NIH NCATS train-
ing sets.
4.2. Screening of the REACH PRS inventory
The four selected models were used to predict 72,524 REACH
PRS in order to give an estimate of the number of PXR activators
and CYP3A4 inducers in this chemical universe (Table 3). A large
overlap in the chemical similarity of small molecule drugs and
Fig. 2. Overlap of positive results between two endpoints and two-way concordance rates. a) comparing tested/predicted hPXR-LBD binders with hPXR activators, b)
comparing tested/predicted hPXR activators with CYP3A4 inducers, and c) comparing tested/predicted rPXR activators with hPXR activators.
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environmental chemicals has been identified, and other QSAR
models trained on drug data have been shown to have a high pre-
dictability of environmental chemicals [52,55,56]. This, together
with the application of a structural AD to avoid extrapolations, jus-
tifies the use of the drug-data trained models to screen the REACH
set. The screening indicates that the predicted REACH PRS set con-
tains nearly the same rate of human and rat PXR full-length activa-
tors as well as CYP3A4 inducers compared to the experimentally
tested drugs in the training sets, i.e. 16% vs. 13%, 6% vs. 5.8%, and
14% vs. 11%, respectively. The hPXR-LBD model, however, pre-
dicted 26% of the REACH PRS inside the model’s AD to be hPXR-
LBD ligands, which was remarkably higher than the 9.3% hPXR-
LBD active drugs in the training set. Since the hPXR-LBD model
does not seem to be biased towards producing many false positive
predictions based on the high specificity in the three validations,
i.e.80.4% to 87.8% (Table 2), this is unlikely the only reason for
the high prevalence of predicted hPXR-LBD actives in the REACH
PRS set. The increased focus on attenuation of PXR activity and
the introduction of a filtering procedure in early drug development
[30] might to some degree explain the nearly three-fold lower rate
of hPXR-LBD ligands among drugs compared to the predicted
REACH substances.
4.3. Concordance rates between endpoints
The calculated concordance rates between endpoints using
either experimental test results or QSAR predictions can provide
information on the frequencies of the possible mechanisms by
which chemicals act as well as reveal differences and similarities
between the two chemical inventories (Fig. 2). Results from a pre-
vious study indicate that differences in the biological mechanisms
of drugs and environmental chemicals exist [58]. When concor-
dance rates are based on QSAR predictions, they can be influenced
by the uncertainty inherent in the predictive models, but since all
four models had high predictive performances in the external val-
idations (Table 2), we expect this uncertainty to be fairly low. For
the concordance rates based on the experimental data, these can
be affected by the fact that experimental tests may not be 100%
reproducible. In a follow-up study, Shukla and colleagues [14]
retested 72 compounds in the four qHTS assays and the activities
were confirmed for 71 (hPXR-LBD), 66 (hPXR), 72 (rPXR) and 70
(CYP3A4) of the compounds, respectively, with no information of
the activity distribution. This could indicate a slightly higher rate
of false positive and/or false negative test results in the hPXR assay
compared to the other three assays. Inclusion of false positives
and/or negatives in the hPXR experimental data could in this case
have affected the hPXR model development and its performance
measurements as well as the subsequent concordance rate studies
of both the experimental and predicted datasets.
Roughly half of the hPXR-LBD binders were also hPXR activators
for both the tested drugs (44%) and the predicted REACH PRS (52%)
(Fig. 2a). This may reflect that the 50% active compounds from
the hPXR-LBD cell-free assay that are not active in the cell-based
hPXR activation assay either cannot enter the cell, are biodegraded
in the cellular environment, or act as human PXR antagonists
[14,28]. For the hPXR activators that were also hPXR-LBD ligands,
we observed a difference in the concordance rates between the
two universes, with only 38% of the full-length hPXR activators
being hPXR-LBD ligands for the tested drugs as opposed to 81%
for the QSAR-predicted REACH PRS. This difference might be a
reflection of the approximately three-times higher occurrence of
predicted hPXR-LBD binders in the QSAR-predicted REACH PRS
universe and thus a higher chance for hPXR activators to also be
predicted active by hPXR-LBD. The part of the hPXR activators that
were not hPXR-LBD ligands likely exert their effect on PXR activa-
tion through other signaling pathways such as protein kinase path-
ways [50,51]. They may also be chemicals that are not able to
displace the tracer molecule in the hPXR-LBD assay [14], a known
problem with LanthaScreen TR-FRET-based binding assays.
When comparing hPXR activation and CYP3A4 induction higher
concordance rates were found for the QSAR-predicted REACH PRS
than for the tested drugs (Fig. 2b). Among the REACH PRS predic-
tions, 88.4% of the hPXR activators also induced CYP3A4, while
for the experimentally tested drugs this was only the case for
53.5% of the hPXR activators. Multiple factors can explain the
absence of CYP3A4 induction by hPXR activators, for example, neg-
ative feedback loops repressing CYP3A4 expression, differences in
recruitment of co-activators resulting in variations in the promoter
region binding and downstream gene transcription patterns [59],
as well as assay-related biochemical limitations [60]. Of the
CYP3A4 inducers, 97.5% and 66.5% of the predicted REACH PRS
and tested drugs, respectively, were also hPXR activators. An expla-
nation to why some CYP3A4 inducers were not hPXR activators
could be that other transcription factors or signaling pathways in
the cell have led to the CYP3A4 induction. The high concordance
rates of 97.5% and 88.4% between the prediction sets indicate that
the two models have high agreement in their predictions.
Previous studies have reported species differences between
human and rat PXR ligands [14,15,52,61] and this is supported
by a highly divergent inter-species PXR-LBD amino acid sequence
[11] with human and rat PXR-LBD sharing only 78.3% amino acid
sequence similarity according to a calculation made using the
web-based SeqAPASS software [62]. In the present study, around
25% of the hPXR activators among both the tested drugs and the
predicted REACH PRS were also activating rPXR (Fig. 2c). Among
the rPXR activators 57–60% in both universes were also activating
hPXR. These results support that species differences in chemical
action of drugs and REACH substances on PXR exist. The current
study has identified 3361 (2788 + 573) REACH substances for
which extra attention is necessary when extrapolating rat in vivo
data to humans.
Overall, this statistical analysis indicates that QSAR predictions
of larger chemical inventories can be applied to study overlap in
activities between biological endpoints. Such studies can poten-
tially be used in hypotheses generation of new mechanistic
associations.
5. Conclusions
We have developed four QSAR models for human PXR-LBD
binding, human and rat full-length PXR activation, and human
CYP3A4 induction. All four models were robust with high predic-
tive performances. The models were used to screen a set of
72,524 REACH PRS and of the QSAR-predicted REACH substances
the number of actives were as follows; hPXR-LBD (11,490), hPXR
(6167), rPXR (3141), and CYP3A4 (5874). Furthermore, the experi-
mental data and the predictions of the REACH substances were
analyzed to obtain information on co-occurrences of positive
results for PXR activation and CYP3A4 induction in the two chem-
ical universes. The developed models can in a fast and cost-
efficient way provide information that can be used for prioritiza-
tion purposes as well as in combination with other data in IATAs
including weight-of-evidence assessments of chemical substances.
The models can also help in future design of safer chemicals and
drugs.
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